Relapse rates after withdrawal versus maintaining biologic therapy in IBD patients with prolonged remission-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Relapse rates after withdrawal versus maintaining biologic therapy in IBD patients with prolonged remission

Published:2023-01-12 Issue:6 Volume:23 Page:2789-2797
ISSN:1591-9528
Container-title:Clinical and Experimental Medicine
language:en
Short-container-title:Clin Exp Med

Author:

Stoker Annemay M. H.,Logghe Leslie,van der Ende-van Loon Mirjam C. M.,Schoon Erik J.,Schreuder Ramon-Michel,Stronkhorst Arnold,Gilissen Lennard P. L.

Publisher

Springer Science and Business Media LLC

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s10238-023-00994-6.pdf

Reference32 articles.

1. Caviglia F, Ribolsi M, Rizzi M, Emerenziani S, Annunziata ML, Cicala M. Maintenance of remission with infliximab in inflammatory bowel disease: efficacy and safety long-term follow-up. World J Gastroenterol. 2007;13:5238–44.

2. Kitayama M, Akazawa Y, Yoshikawa D, et al. Comparative efficacy of antitumor necrosis factor agents and tacrolimus in naïve steroid-refractory ulcerative colitis patients. Sci Rep. 2020;10:12546.

3. D’Haens G, Baert F, Van Assche G, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn’s disease: an open randomised trial. Lancet. 2008;371:660–7.

4. Shivaji UN, Sharratt CL, Thomas T, et al. Review article: managing the adverse events caused by anti-TNF therapy in inflammatory bowel disease. Aliment Pharmacol Ther. 2019;49:664–80.

5. Hoentjen F, Van Bodegraven A. Safety of anti-tumor necrosis factor therapy in inflammatory bowel disease. World J Gastroenterol. 2009;15:2067–73.

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Inflammatory bowel disease alters in vivo distribution of orally administrated nanoparticles: Revealing via SERS tag labeling technique;Talanta;2024-08

2. De-escalating therapy in inflammatory bowel disease: Results from an observational study in clinical practice;Gastroenterología y Hepatología;2023-08

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3